ENTA

ENANTA PHARMACEUTICALS, INC

ENTA · CIK 1177648 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$65M
20182025
Net Income−$82M
20182025
Operating CF−$19M
20182025
Free Cash Flow−$32M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.1B$0.1B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.2B$0.2B$0.2B$0.1B$0.1B$0.1B
SG&A Expense————————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$0.0B$0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$0.0B$0.0B
EPS (Basic)$-3.84$-5.48$-6.38$-5.91$-3.92$-1.46$0.47$1.41
EPS (Diluted)$-3.84$-5.48$-6.38$-5.91$-3.92$-1.46$0.44$1.30

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.3B$0.4B$0.5B$0.4B$0.4B$0.5B$0.5B$0.4B
Current Assets$0.2B$0.3B$0.4B$0.3B$0.3B$0.4B$0.4B$0.4B
Cash & Equivalents$0.0B$0.0B$0.1B$0.0B$0.1B$0.1B$0.1B$0.1B
Total Liabilities$0.2B$0.2B$0.2B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.2B$0.3B$0.4B$0.5B$0.5B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B$0.0B$0.1B$0.0B
Investing Cash Flow$0.0B$0.1B$-0.1B$0.1B$0.0B$0.0B$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$-0.0B$0.2B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies